Intersect ENT, Inc. (NASDAQ:XENT) Director Frederic H. Moll sold 800 shares of the business’s stock in a transaction on Friday, November 10th. The stock was sold at an average price of $29.00, for a total value of $23,200.00. Following the completion of the transaction, the director now directly owns 253,824 shares in the company, valued at approximately $7,360,896. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.
Intersect ENT, Inc. (XENT) traded up $0.45 during midday trading on Tuesday, reaching $28.60. The company had a trading volume of 293,400 shares, compared to its average volume of 292,953. Intersect ENT, Inc. has a fifty-two week low of $9.20 and a fifty-two week high of $33.25.
Intersect ENT (NASDAQ:XENT) last announced its quarterly earnings results on Thursday, November 2nd. The medical equipment provider reported ($0.15) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.20) by $0.05. Intersect ENT had a negative return on equity of 15.96% and a negative net margin of 19.81%. The company had revenue of $22.31 million during the quarter, compared to the consensus estimate of $21.53 million. During the same period in the prior year, the company earned ($0.22) earnings per share. The company’s revenue for the quarter was up 20.8% compared to the same quarter last year. equities analysts expect that Intersect ENT, Inc. will post -0.63 EPS for the current fiscal year.
A number of research firms have commented on XENT. BTIG Research reissued a “hold” rating on shares of Intersect ENT in a research note on Tuesday, November 7th. Northland Securities restated a “hold” rating and set a $25.00 target price on shares of Intersect ENT in a research report on Friday, November 3rd. Zacks Investment Research downgraded Intersect ENT from a “buy” rating to a “hold” rating in a research report on Wednesday, November 1st. Canaccord Genuity boosted their target price on Intersect ENT from $32.00 to $37.00 and gave the stock a “buy” rating in a research report on Wednesday, September 13th. Finally, Bank of America Corporation boosted their target price on Intersect ENT from $33.00 to $40.00 and gave the stock a “buy” rating in a research report on Monday, September 11th. Five equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $30.88.
Several institutional investors have recently made changes to their positions in XENT. Great West Life Assurance Co. Can bought a new stake in shares of Intersect ENT in the third quarter worth about $116,000. Oppenheimer Asset Management Inc. acquired a new position in shares of Intersect ENT during the third quarter worth about $117,000. Legal & General Group Plc boosted its position in shares of Intersect ENT by 3.8% during the second quarter. Legal & General Group Plc now owns 6,939 shares of the medical equipment provider’s stock worth $193,000 after buying an additional 255 shares during the period. Moors & Cabot Inc. acquired a new position in shares of Intersect ENT during the second quarter worth about $205,000. Finally, Campbell & CO Investment Adviser LLC acquired a new position in shares of Intersect ENT during the third quarter worth about $228,000. Institutional investors own 80.23% of the company’s stock.
Intersect ENT Company Profile
Intersect ENT, Inc is a commercial-stage drug-device company. The Company develops drugs for patients with ear, nose and throat (ENT) conditions. The Company has developed a drug releasing bioabsorbable implant technology that enables targeted and sustained release of therapeutic agents. This targeted drug delivery technology is designed to allow ENT physicians to manage patient care.
Receive News & Ratings for Intersect ENT Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intersect ENT Inc. and related companies with MarketBeat.com's FREE daily email newsletter.